<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01695954</url>
  </required_header>
  <id_info>
    <org_study_id>11-01787</org_study_id>
    <nct_id>NCT01695954</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz</brief_title>
  <official_title>The Effect of Efavirenz and Ritonavir-boosted Darunavir on the Pharmacokinetics of the HMG CoA Reductase Inhibitor Pitavastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York City Health and Hospitals Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kowa Pharmaceuticals America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to determine how taking efavirenz affects the levels of&#xD;
      pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir&#xD;
      with ritonavir affects the levels of pitavastatin in the bloodstream. Secondary goals are to&#xD;
      see how taking pitavastatin affects the levels in the blood of efavirenz when both drugs are&#xD;
      taken together and to see how taking pitavastatin affects the levels in the blood of&#xD;
      darunavir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infected persons are at risk for coronary heart disease due to chronic inflammation&#xD;
      associated with the virus itself, the side effects of the antiretroviral (ARV) therapies&#xD;
      which can cause elevated cholesterol, and the risk factors such as smoking, high blood&#xD;
      pressure and family history of heart disease.&#xD;
&#xD;
      The most commonly prescribed ARVs for treatment of HIV are efavirenz and drugs in the&#xD;
      protease inhibitor (PI) class such as darunavir with ritonavir. To treat elevated cholesterol&#xD;
      in patients infected with HIV, guidelines recommend the use of statins (a class of lipid&#xD;
      lowering drugs). PIs and efavirenz can increase the levels of some statins and reduce the&#xD;
      levels of others in the bloodstream. Pitavastatin (Livalo) is a statin approved by the Food&#xD;
      and Drug Administration (FDA) for the treatment of high cholesterol.&#xD;
&#xD;
      In order to be able to use pitavastatin safely in HIV-infected patients taking either&#xD;
      darunavir with ritonavir or efavirenz, it is important to study how taking pitavastatin with&#xD;
      darunavir and ritonavir or pitavastatin with efavirenz affect the levels of each of these&#xD;
      drugs in the bloodstream.&#xD;
&#xD;
      Twenty-eight participants will be enrolled in one of two study arms: 14 in Arm A and 14 in&#xD;
      Arm B.&#xD;
&#xD;
      Arm A:&#xD;
&#xD;
      Participants will start taking pitavastatin 2 mg tablets every night at bedtime. On day 4&#xD;
      participants will come in for a 14-hour pharmacokinetic (PK) overnight visit and will have&#xD;
      about 9 tablespoons of blood drawn. Participants will return 12 hours after the last blood&#xD;
      draw for a final blood draw. They will then stop taking pitavastatin. Participants will then&#xD;
      start taking one efavirenz 600 mg tablet at bedtime.&#xD;
&#xD;
      On day 14, participants will come in for a second 14-hour visit and will have about 9&#xD;
      tablespoons of blood drawn. They will return 12 hour after the last blood draw for a final&#xD;
      blood draw. Participants will then start taking both pitavastatin and efavirenz at bedtime.&#xD;
&#xD;
      On day 18, participants will come in for a third 14-hour PK visit and will have about 9&#xD;
      tablespoons of blood drawn. They will return 12 hour after the last blood draw for a final&#xD;
      blood draw. They will then stop taking all study drugs and will either come in or receive a&#xD;
      final phone call on day 25.&#xD;
&#xD;
      Arm B:&#xD;
&#xD;
      Participants will start taking one pitavastatin 2 mg tablet every morning. On day 4&#xD;
      participants will come in for a 14-hour pharmacokinetic (PK) daytime visit and will have&#xD;
      about 9 tablespoons of blood drawn. Participants will return 12 hours after the last blood&#xD;
      draw for a final blood draw. They will then stop taking pitavastatin. Participants will then&#xD;
      start taking darunavir 400 mg tablets (2) and ritonavir 100 mg tablets (1) every morning.&#xD;
&#xD;
      On day 14, participants will come in for a second 14-hour visit and will have about 9&#xD;
      tablespoons of blood drawn. They will return 12 hour after the last blood draw for a final&#xD;
      blood draw. Participants will then start taking one pitavastatin 2mg tablet, two darunavir&#xD;
      400 mg tablets and one ritonavir 100 mg tablet.&#xD;
&#xD;
      On day 18, participants will come in for a third 14-hour PK visit and will have about 9&#xD;
      tablespoons of blood drawn. They will return 12 hour after the last blood draw for a final&#xD;
      blood draw. They will then stop taking all study drugs and will either come in or receive a&#xD;
      final phone call on day 25.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>24-hour area under the curve (AUC) for pitavastatin when coadministered with efavirenz and with darunavir/ritonavir and 24-hour AUC for efavirenz or darunavir when coadministered with pitavastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMR of 24- Hour AUC of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir Over 24 Hour AUC of Pitavastatin</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio (GMR) of 24- Hour Area under the plasma drug concentration-time curve (AUC) of pitavastatin when coadministered with efavirenz or with darunavir/ritonavir over 24 Hour (AUC) of pitavastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMR of Cmax of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir</measure>
    <time_frame>Day 18</time_frame>
    <description>Geometric Mean Ratio (GMR) of Cmax for pitavastatin with Efavirenz vs. alone and GMR of Cmax for pitavastatin with darunavir/ritonavir vs. alone was reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Livalo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir 400 mg tablets x 2 taken daily in Arm B</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100 mg tablets taken daily in Arm B</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz 600 mg tablets taken at bedtime in Arm A</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Sustiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Male or female aged 18-60 years.&#xD;
&#xD;
          -  Able and willing to provide informed consent.&#xD;
&#xD;
          -  All men and women of reproductive potential must practice adequate birth control to&#xD;
             prevent pregnancy from start of the study until completion of the study.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 14 days prior to study entry and day of entry.&#xD;
&#xD;
          -  Hemoglobin &gt; 12.5 g/dL for men; &gt; 11.5 g/dL for women;&#xD;
&#xD;
          -  Absolute neutrophil count &gt;1,500 cells/mm3;&#xD;
&#xD;
          -  Platelet count &gt; 100,000 platelets/mm3;&#xD;
&#xD;
          -  AST (SGOT)/ALT (SGPT) &lt;1.5X ULN;&#xD;
&#xD;
          -  Creatinine &lt;1.5 X ULN&#xD;
&#xD;
          -  Subject is within 20% (+/-) of ideal body weight and must weigh at least 50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of illicit drugs or alcohol which would interfere with the completion of this&#xD;
             study.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  History of chronic illnesses such as hypertension, coronary artery disease, arthritis,&#xD;
             diabetes, or any chronic gastrointestinal conditions which might interfere with drug&#xD;
             absorption.&#xD;
&#xD;
          -  Any medical condition which, in the opinion of the investigator, would interfere with&#xD;
             the subjects ability to participate in this protocol.&#xD;
&#xD;
          -  Use of prohibited protocol-specified drugs, prescription or over-the-counter within 14&#xD;
             days prior to study entry.&#xD;
&#xD;
          -  Participation in any investigational drug studies within 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Aberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue/NYU AIDS Clinical Trials Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6. doi: 10.1097/QAI.0000000000000333.</citation>
    <PMID>25202920</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2012</study_first_posted>
  <results_first_submitted>January 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2020</results_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Statins</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Pitavastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Accrual began August 24, 2012 and ended January, 8, 2013. All study procedures took place at the NYU/Bellevue Clinical Trials Unit and NYU Clinical and Translational Science Institute.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: (Pitavastatin and Efavirenz)</title>
          <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: (Pitavastatin and Ritonavir-boosted Darunavir)</title>
          <description>Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: (Pitavastatin and Efavirenz)</title>
          <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: (Pitavastatin and Ritonavir-boosted Darunavir)</title>
          <description>Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>24-hour area under the curve (AUC) for pitavastatin when coadministered with efavirenz and with darunavir/ritonavir and 24-hour AUC for efavirenz or darunavir when coadministered with pitavastatin</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Subjects who completed all visits</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: (Pitavastatin and Efavirenz)</title>
            <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime for the first 4 days, then efavirenz 600 mg at bedtime for the next 10 days and both pitavastatin 2 mg and efavirenz 600 mg at bedtime for the final 4 days. Blood will be drawn on days 0, 4, 14 and 18.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: (Pitavastatin and Darunavir)</title>
            <description>Subjects in arm will receive pitavastatin 2 mg daily for the first 4 days, then darunavir 400 mg x 2 tabs and ritonavir 100 mg x 1 tab daily for the next 10 days and will receive both pitavastatin 2 mg and darunavir 400 mg x 2 tabs and ritonavir 100 mg x 1 tab daily for the final 4 days. Blood will be drawn on days 0, 4, 14, and 18.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>24-hour area under the curve (AUC) for pitavastatin when coadministered with efavirenz and with darunavir/ritonavir and 24-hour AUC for efavirenz or darunavir when coadministered with pitavastatin</description>
          <population>Subjects who completed all visits</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="5.72"/>
                    <measurement group_id="O2" value="62.8" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMR of Cmax of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir</title>
        <description>Geometric Mean Ratio (GMR) of Cmax for pitavastatin with Efavirenz vs. alone and GMR of Cmax for pitavastatin with darunavir/ritonavir vs. alone was reported.</description>
        <time_frame>Day 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: (Pitavastatin and Efavirenz)</title>
            <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: (Pitavastatin and Ritonavir-boosted Darunavir)</title>
            <description>Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>GMR of Cmax of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir</title>
          <description>Geometric Mean Ratio (GMR) of Cmax for pitavastatin with Efavirenz vs. alone and GMR of Cmax for pitavastatin with darunavir/ritonavir vs. alone was reported.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="0.79" upper_limit="1.83"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.72" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMR of 24- Hour AUC of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir Over 24 Hour AUC of Pitavastatin</title>
        <description>Geometric Mean Ratio (GMR) of 24- Hour Area under the plasma drug concentration-time curve (AUC) of pitavastatin when coadministered with efavirenz or with darunavir/ritonavir over 24 Hour (AUC) of pitavastatin</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Subjects who completed all visits</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: (Pitavastatin and Efavirenz)</title>
            <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime for the first 4 days, then efavirenz 600 mg at bedtime for the next 10 days and both pitavastatin 2 mg and efavirenz 600 mg at bedtime for the final 4 days. Blood will be drawn on days 0, 4, 14 and 18.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: (Pitavastatin and Darunavir)</title>
            <description>Subjects in arm will receive pitavastatin 2 mg daily for the first 4 days, then darunavir 400 mg x 2 tabs and ritonavir 100 mg x 1 tab daily for the next 10 days and will receive both pitavastatin 2 mg and darunavir 400 mg x 2 tabs and ritonavir 100 mg x 1 tab daily for the final 4 days. Blood will be drawn on days 0, 4, 14, and 18.</description>
          </group>
        </group_list>
        <measure>
          <title>GMR of 24- Hour AUC of Pitavastatin When Coadministered With Efavirenz or With Darunavir/Ritonavir Over 24 Hour AUC of Pitavastatin</title>
          <description>Geometric Mean Ratio (GMR) of 24- Hour Area under the plasma drug concentration-time curve (AUC) of pitavastatin when coadministered with efavirenz or with darunavir/ritonavir over 24 Hour (AUC) of pitavastatin</description>
          <population>Subjects who completed all visits</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMR of Pitavastatin with (EFV or DRV)/Pitavastatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".89" lower_limit=".7321" upper_limit="1.09"/>
                    <measurement group_id="O2" value=".91" lower_limit=".78" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMR of (EFV or DRV) with Pitavastatin/(EFV or DRV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" lower_limit=".75" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.08" lower_limit=".96" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: (Pitavastatin and Efavirenz)</title>
          <description>Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: (Pitavastatin and Ritonavir-boosted Darunavir)</title>
          <description>Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>CPK elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at venipuncture site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pitavastatin levels for 4 subjects enrolled in Arm B were lost due to emergency transfer of specimens to temporary storage facility during Hurricane Sandy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carlos Malvestutto, MD, MPH</name_or_title>
      <organization>NYU School of Medicine</organization>
      <phone>212-263-3570</phone>
      <email>carlos.malvestutto@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

